Page 149 - Read Online

Page 10 of 12 Kamiya et al. J Cancer Metastasis Treat 2018;4:35 I http://dx.doi.org/10.20517/2394-4722.2017.76

outcomes after endoscopic resection for early gastric cancer: 1370 cases of absolute and extended indications. Gastrointest Endosc
2011;74:485-93.
22. Park CH, Shin S, Park JC, Shin SK, Lee SK, Lee YC, Lee H. Long-term outcome of early gastric cancer after endoscopic submucosal
dissection: expanded indication is comparable to absolute indication. Dig Liver Dis 2013;45:651-6.
23. Hotta K, Oyama T, Akamatsu T, Tomori A, Hasebe O, Nakamura N, Kojima E, Suga T, Miyabayashi H, Ohta H. A comparison of outcomes
of endoscopic submucosal dissection (ESD) for early gastric neoplasms between high-volume and low-volume centers: multi-center
retrospective questionnaire study conducted by the Nagano ESD Study Group. Intern Med 2010;49:253-9.
24. Oda I, Saito D, Tada M, Iishi H, Tanabe S, Oyama T, Doi T, Otani Y, Fujisaki J, Ajioka Y, Hamada T, Inoue H, Gotoda T, Yoshida S. A
multicenter retrospective study of endoscopic resection for early gastric cancer. Gastric Cancer 2006;9:262-70.
25. van der Wielen N, Straatman J, Cuesta MA, Daams F, van der Peet DL. Short-term outcomes in minimally invasive versus open
gastrectomy: the differences between East and West. A systematic review of the literature. Gastric Cancer 2018;21:19-30.
26. Park S, Chung HY, Lee SS, Kwon O, Yu W. Serial comparisons of quality of life after distal subtotal or total gastrectomy: what are the
rational approaches for quality of life management? J Gastric Cancer 2014;14:32-8.
27. Davies J, Johnston D, Sue-Ling H, Young S, May J, Griffith J, Miller G, Martin I.Total or subtotal gastrectomy for gastric carcinoma? A
study of quality of life. World J Surg 1998;22:1048-55.
28. Hiki N, Nunobe S, Kubota T, Jiang X. Function-preserving gastrectomy for early gastric cancer. Ann Surg Oncol 2013;20:2683-92.
29. Kosuga T, Hiki N, Nunobe S, Noma H, Honda M, Tanimura S, Sano T, Yamaguchi T. Feasibility and nutritional impact of laparoscopy-
assisted subtotal gastrectomy for early gastric cancer in the upper stomach. Ann Surg Oncol 2014;21:2028-35.
30. Jiang X, Hiki N, Nunobe S, Nohara K, Kumagai K, Sano T, Yamaguchi T. Laparoscopy-assisted subtotal gastrectomy with very small
remnant stomach: a novel surgical procedure for selected early gastric cancer in the upper stomach. Gastric Cancer 2011;14:194-9.
31. Postlewait LM, Squires MH 3rd, Kooby DA, Poultsides GA, Weber SM, Bloomston M, Fields RC, Pawlik TM, Votanopoulos KI, Schmidt
CR, Ejaz A, Acher AW, Worhunsky DJ, Saunders N, Swords D, Jin LX, Cho CS, Winslow ER, Cardona K, Staley CA, Maithel SK. The
importance of the proximal resection margin distance for proximal gastric adenocarcinoma: a multi-institutional study of the US Gastric
Cancer Collaborative. J Surg Oncol 2015;112:203-7.
32. Numata N, Oka S, Tanaka S, Kagemoto K, Sanomura Y, Yoshida S, Arihiro K, Shimamoto F, Chayama K. Risk factors and management of
positive horizontal margin in early gastric cancer resected by en bloc endoscopic submucosal dissection. Gastric Cancer 2015;18:332-8.
33. Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, Welvaart K, van Krieken JH, Meijer S, Plukker
JT, van Elk PJ, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H, Sasako M. Extended
lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol
2004;22:2069-77.
34. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the
randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010;11:439-49.
35. Kung CH, Lindblad M, Nilsson M, Rouvelas I, Kumagai K, Lundell L, Tsai JA. Postoperative pancreatic fistula formation according to
ISGPF criteria after D2 gastrectomy in Western patients. Gastric Cancer 2014;17:571-7.
36. Uyama I, Sugioka A, Matsui H, Fujita J, Komori Y, Hasumi A. Laparoscopic D2 lymph node dissection for advanced gastric cancer located
in the middle or lower third portion of the stomach. Gastric Cancer 2000;3:50-5.
37. Kitano S, Shiraishi N, Fujii K, Yasuda K, Inomata M, Adachi Y. A randomized controlled trial comparing open vs laparoscopy-assisted
distal gastrectomy for the treatment of early gastric cancer: an interim report. Surgery 2002;131:S306-11.
38. Lee JH, Han HS, Lee JH. A prospective randomized study comparing open vs laparoscopy-assisted distal gastrectomy in early gastric
cancer: early results. Surg Endosc 2005;19:168-73.
39. Kim HH, Hyung WJ, Cho GS, Kim MC, Han SU, Kim W, Ryu SW, Lee HJ, Song KY. Morbidity and mortality of laparoscopic gastrectomy
versus open gastrectomy for gastric cancer: an interim report--a phase III multicenter, prospective, randomized trial (KLASS Trial). Ann
Surg 2010;251:417-20.
40. Zou ZH, Zhao LY, Mou TY, Hu YF, Yu J, Liu H, Chen H, Wu JM, An SL, Li GX. Laparoscopic vs open D2 gastrec- tomy for locally
advanced gastric cancer: a meta-analysis. World J Gastroenterol 2014;20:16750-64.
41. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM,
Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal
junction. N Engl J Med 2001;345:725-30.
42. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB,
Langley RE, Verma M, Weeden S, Chua YJ. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N
Engl J Med 2006;355:11-20.
43. Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, Probst
S, Koenigsmann M, Egger M, Prasnikar N, Caca K, Trojan J, Martens UM, Block A, Fischbach W, Mahlberg R, Clemens M, Illerhaus
G, Zirlik K, Behringer DM, Schmiegel W, Pohl M, Heike M, Ronellenfitsch U, Schuler M, Bechstein WO, Königsrainer A, Gaiser
T, Schirmacher P, Hozaeel W, Reichart A, Goetze TO, Sievert M, Jäger E, Mönig S, Tannapfel A. Histopathological regression after
neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with
resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label,
randomised phase 2/3 trial. Lancet Oncol 2016;17:1697-708.
44. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M,
Yamamura Y, Kurita A, Arai K; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J
Med 2007;357:1810-20.
45. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P,
Sirzen F, Noh SH; CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC):